2LBA Late Breaking - Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC)

B.C Cho,S Stopatschinskaja,D Trone,R Diadziuskzko,E Felip,S.W Kim,B Solomon,V Velcheti,K.H Lee,Muhammad Shaalan Beg ,Christoph Springfeld ,Benjamin Besse ,Sheng Lu ,Juergen Wolf ,Jessica J Lin ,D Ross Camidge ,Sanjay Popat ,Misako Nagasaka ,Steven Kao ,Alexander Drilon

doi:10.1016/s0959-8049(22)00812-7

Abstract

Background: Repotrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) currently under evaluation in the global phase 1/2 TRIDENT-1 trial (NCT03093116). We report updated results in TKI-naïve and -pretreated patients with advanced, ROS1 fusion-positive (ROS1+) NSCLCs.

Full Text